50m
Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update
Positive 12-month Phase 2 data for NDV-01 in non-muscle invasive bladder cancer (NMIBC) demonstrated a 95% complete response (CR) rate at any time and a durable 76% CR rate at 12 months, with ...
These are courtesy translations of local news provided by the U.S. Army Garrison Poland Public Affairs team for the benefit ...
Western Alliance Bank (NYSE: WAL) today announced a $100,000 donation from the Western Alliance Community Foundation, which serves as the bank’s charitable arm, to support the launch of a new veterans ...
Q4 2025 product sales of $21.3 million, representing 83% growth over Q4 2024Q4 2025 basic GAAP EPS of $0.06, fully diluted GAAP EPS of $0.05, basic non-GAAP EPS of $0.21, fully diluted non-GAAP EPS of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results